276 related articles for article (PubMed ID: 18953065)
21. AIDS-related central nervous system lymphomas.
Chamberlain MC; Kormanik PA
J Neurooncol; 1999 Jul; 43(3):269-76. PubMed ID: 10563433
[TBL] [Abstract][Full Text] [Related]
22. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
23. Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy.
Korfel A; Thiel E
Leuk Lymphoma; 1998 Aug; 30(5-6):609-17. PubMed ID: 9711923
[TBL] [Abstract][Full Text] [Related]
24. Advantages of dose-dense methotrexate protocol for primary central nervous system lymphoma: comparison of two different protocols at a single institution.
Aoki H; Ogura R; Tsukamoto Y; Okada M; Natsumeda M; Isogawa M; Yoshida S; Fujii Y
Neurol Med Chir (Tokyo); 2013; 53(11):797-804. PubMed ID: 24162244
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of temozolomide plus concurrent whole-brain radiation followed by TNV regimen as adjuvant therapy for patients with newly diagnosed primary CNS lymphoma.
Wang Y; Liu B; Xu D; Zhao H; Zhu Y; Xu J; Tao R
Neurol India; 2013; 61(3):260-4. PubMed ID: 23860145
[TBL] [Abstract][Full Text] [Related]
26. Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma.
Faivre G; Butler MJ; Le I; Brenner A
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):665-669. PubMed ID: 31351990
[TBL] [Abstract][Full Text] [Related]
27. Prophylactic intrathecal chemotherapy in primary CNS lymphoma.
Sierra Del Rio M; Ricard D; Houillier C; Navarro S; Gonzalez-Aguilar A; Idbaih A; Kaloshi G; Elhallani S; Omuro A; Choquet S; Soussain C; Hoang-Xuan K
J Neurooncol; 2012 Jan; 106(1):143-6. PubMed ID: 21739169
[TBL] [Abstract][Full Text] [Related]
28. Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy.
Morris PG; Abrey LE; Reiner AS; Wu N; Panageas KS; Seko BS; Deangelis LM; Omuro A
Leuk Lymphoma; 2011 Oct; 52(10):1891-7. PubMed ID: 21699456
[TBL] [Abstract][Full Text] [Related]
29. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.
Pels H; Schmidt-Wolf IG; Glasmacher A; Schulz H; Engert A; Diehl V; Zellner A; Schackert G; Reichmann H; Kroschinsky F; Vogt-Schaden M; Egerer G; Bode U; Schaller C; Deckert M; Fimmers R; Helmstaedter C; Atasoy A; Klockgether T; Schlegel U
J Clin Oncol; 2003 Dec; 21(24):4489-95. PubMed ID: 14597744
[TBL] [Abstract][Full Text] [Related]
30. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I
Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253
[TBL] [Abstract][Full Text] [Related]
31. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.
Poortmans PM; Kluin-Nelemans HC; Haaxma-Reiche H; Van't Veer M; Hansen M; Soubeyran P; Taphoorn M; Thomas J; Van den Bent M; Fickers M; Van Imhoff G; Rozewicz C; Teodorovic I; van Glabbeke M;
J Clin Oncol; 2003 Dec; 21(24):4483-8. PubMed ID: 14597741
[TBL] [Abstract][Full Text] [Related]
32. Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma.
Sung KH; Lee EH; Kim YZ
J Korean Med Sci; 2011 Apr; 26(4):551-60. PubMed ID: 21468264
[TBL] [Abstract][Full Text] [Related]
33. Primary central nervous system lymphoma: a role for adjuvant chemotherapy.
Chamberlain MC; Levin VA
J Neurooncol; 1992 Nov; 14(3):271-5. PubMed ID: 1460490
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center.
Welch MR; Omuro A; Deangelis LM
Neuro Oncol; 2012 Oct; 14(10):1304-11. PubMed ID: 22952196
[TBL] [Abstract][Full Text] [Related]
35. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.
Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T
Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957
[TBL] [Abstract][Full Text] [Related]
36. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
Martinez-Calle N; Poynton E; Alchawaf A; Kassam S; Horan M; Rafferty M; Kelsey P; Scott G; Culligan DJ; Buckley H; Lim YJ; Ngu L; McCulloch R; Rowntree C; Wright J; McKay P; Fourali S; Eyre TA; Smith J; Osborne W; Yallop D; Linton K; Fox CP; Cwynarski K
Br J Haematol; 2020 Aug; 190(3):394-404. PubMed ID: 32232989
[TBL] [Abstract][Full Text] [Related]
38. Tailored therapy for aggressive non-Hodgkin's lymphoma: results of a phase II study with a long-term follow-up.
Palmieri G; Morabito A; Rea A; Biondi E; Lauria R; Matano E; Pagliarulo C; Montesarchio V; Tagliaferri P; Bianco AR
Int J Oncol; 1998 Jul; 13(1):121-7. PubMed ID: 9625813
[TBL] [Abstract][Full Text] [Related]
39. Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination.
Ferreri AJ; Licata G; Foppoli M; Corazzelli G; Zucca E; Stelitano C; Zaja F; Fava S; Paolini R; Franzin A; Politi LS; Ponzoni M; Reni M
Oncologist; 2011; 16(3):336-41. PubMed ID: 21346023
[TBL] [Abstract][Full Text] [Related]
40. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
